Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK

Abstract

Lentigo maligna (LM) is an in situ melanoma that arises on chronically sun-damaged skin, predominantly on the head and neck. While surgery is the gold standard treatment for LM, imiquimod 5% (Aldara®), an immune response modifier, is a well-reported off-licence treatment in both primary and adjuvant settings. Although NICE suggests considering treatment with imiquimod, there are, as yet, no formal guidelines.